The Effectiveness of Elranatamab in the Management of Refractory Multiple Myeloma with Central Nervous System...

Multiple myeloma with central nervous system (CNS) involvement is rare and associated with a poor prognosis. Although the emergence of novel therapies, including chimeric antigen receptor T-cell therapy and bispecific antibodies, has made it possible to obtain long-term disease control in multiple myeloma, there is still no established standard treatment for cases with CNS involvement, and the efficacy of novel therapies remains unclear. To our knowledge, we herein report the first case of successful elranatamab treatment in Japan in a patient with refractory multiple myeloma showing impaired consciousness caused by CNS involvement.